PMID- 21151616
OWN - NLM
STAT- MEDLINE
DCOM- 20110404
LR  - 20211203
IS  - 1110-7251 (Electronic)
IS  - 1110-7243 (Print)
IS  - 1110-7243 (Linking)
VI  - 2011
DP  - 2011
TI  - Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
PG  - 928326
LID - 10.1155/2011/928326 [doi]
LID - 928326
AB  - Cardiac hypertrophy occurs in association with heart diseases and ultimately 
      results in cardiac dysfunction and heart failure. Histone deacetylases (HDACs) 
      are post-translational modifying enzymes that can deacetylate histones and 
      non-histone proteins. Research with HDAC inhibitors has provided evidence that 
      the class I HDACs are pro-hypertrophic. Among the class I HDACs, HDAC2 is 
      activated by hypertrophic stresses in association with the induction of heat 
      shock protein 70. Activated HDAC2 triggers hypertrophy by inhibiting the signal 
      cascades of either Kruppel like factor 4 (KLF4) or inositol 
      polyphosphate-5-phosphatase f (Inpp5f). Thus, modulators of HDAC2 enzymes, such 
      as selective HDAC inhibitors, are considered to be an important target for heart 
      diseases, especially for preventing cardiac hypertrophy. In contrast, class IIa 
      HDACs have been shown to repress cardiac hypertrophy by inhibiting 
      cardiac-specific transcription factors such as myocyte enhancer factor 2 (MEF2), 
      GATA4, and NFAT in the heart. Studies of class IIa HDACs have shown that the 
      underlying mechanism is regulated by nucleo-cytoplasm shuttling in response to a 
      variety of stress signals. In this review, we focus on the class I and IIa HDACs 
      that play critical roles in mediating cardiac hypertrophy and discuss the 
      non-histone targets of HDACs in heart disease.
FAU - Kee, Hae Jin
AU  - Kee HJ
AD  - Medical Research Center for Gene Regulation, Chonnam National University Medical 
      School, Gwangju 501-746, Republic of Korea.
FAU - Kook, Hyun
AU  - Kook H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20101129
PL  - United States
TA  - J Biomed Biotechnol
JT  - Journal of biomedicine & biotechnology
JID - 101135740
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (KLF4 protein, human)
RN  - 0 (Klf4 protein, mouse)
RN  - 0 (Kruppel-Like Factor 4)
RN  - EC 3.5.1.98 (Histone Deacetylases)
SB  - IM
MH  - Animals
MH  - Cardiomegaly/*drug therapy/*enzymology
MH  - Histone Deacetylase Inhibitors/*pharmacology
MH  - Histone Deacetylases/*metabolism
MH  - Humans
MH  - Kruppel-Like Factor 4
MH  - Mice
MH  - Molecular Targeted Therapy/methods
PMC - PMC2997602
EDAT- 2010/12/15 06:00
MHDA- 2011/04/05 06:00
PMCR- 2010/11/29
CRDT- 2010/12/15 06:00
PHST- 2010/07/14 00:00 [received]
PHST- 2010/10/27 00:00 [accepted]
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/04/05 06:00 [medline]
PHST- 2010/11/29 00:00 [pmc-release]
AID - 10.1155/2011/928326 [doi]
PST - ppublish
SO  - J Biomed Biotechnol. 2011;2011:928326. doi: 10.1155/2011/928326. Epub 2010 Nov 
      29.